Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
Byoung Chul Cho, MD, PhD
Advertisement
Articles by Byoung Chul Cho, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
HDP-101 Receives FDA Fast Track Designation in Multiple Myeloma
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Raludotatug Deruxtecan Shows Promise in Platinum-Resistant Ovarian Cancer
4
Exa-Cel Improved HRQOL for in Transfusion-Dependent β-Thalassemia
5
